Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles

Journal of Immunology

Volumn 175, Issue 9, 2005, Pages 6211-6218

  Spohn, Gunther ^a   Schwarz, Katrin ^a   Maurer, Patrik ^a   Illges, Harald ^b,c,e   Rajasekaran, Narendiran ^c   Choi, Yongwon ^d   Jennings, Gary T ^a   Bachmann, Martin F ^a  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

^b UNIVERSITY OF KONSTANZ   (Switzerland)

^c UNIVERSITY OF KONSTANZ   (Germany)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; BONE ATROPHY; BONE DISEASE; CONTROLLED STUDY; COVALENT BOND; CROSS LINKING; DRUG COST; FEMALE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTECTION; VIRUS PARTICLE;

EID: 27144468615     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.9.6211     Document Type: Article

References (40)

1. Riggs, B. L., S. Khosla, and L. J. Melton, 3rd. 2002. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23: 279-302.
2. Gowen, M., J. G. Emery, and S. Kumar. 2000. Emerging therapies for osteoporosis. Expert Opin. Emerg. Drugs 5: 1-43.
3. Wong, B. R., J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, E. Cayani, F. S. Bartlett, 3rd, W. N. Frankel, et al. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272: 25190-25194.
4. Anderson, D. M., E. Maraskovsky, W. L. Billingsley, W. C. Dougall, M. E. Tometsko, E. R. Roux, M. C. Teepe, R. F. DuBose, D. Cosman, and L. Galibert. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179.
5. Walsh, M. C., and Y. Choi. 2003. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 14: 251-263.
6. Theill, L. E., W. J. Boyle, and J. M. Penninger. 2002. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20: 795-823.
7. Simonet, W. S., D. L. Lacey, C. R. Dunstan, M. Kelley, M.-S. Chang, R. Luthy, H. Q. Nguyen, S. Wooden, L. Bennett, T. Boone, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
8. Lacey, D. L., E. Timms, H.-L. Tan, M. J. Kelley, C. R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
9. Min, H., S. Morony, I. Sarosi, C. R. Dunstan, C. Capparelli, S. Scully, G. Van, S. Kaufman, P. J. Kostenuik, D. L. Lacey, et al. 2000. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp. Med. 192: 463-474.
10. Redlich, K., S. Hayer, A. Maier, C. R. Dunstan, M. Tohidast-Akrad, S. Lang, B. Turk, P. Pietschmann, W. Woloszczuk, S. Haralambous, et al. 2002. Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46: 785-792.
11. Luger, N. M., P. Honore, M. A. Sabino, M. J. Schwel, S. D. Rogers, D. B. Mach, D. R. Clohisy, and P. W. Mantyh. 2001. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res. 61: 4038-4047.
12. Bekker, P. J., D. Holloway, A. Nakanishi, M. Arrighi, P. T. Leese, and C. R. Dunstan. 2001. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16: 348-360.
13. Body, J. J., P. Greipp, R. E. Coleman, T. Facon, F. Geurs, J. P. Fermand, J. L. Harousseau, A. Lipton, X. Mariette, C. D. Williams, et al. 2003. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97: 887-892.
14. Emery, J. G., P. McDonnell, M. B. Burke, K. C. Deen, S. Lyn, C. Silverman, E. Dul, E. R. Appelbaum, C. Eichman, R. DiPrinzio, et al. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273: 14363-14367.
15. Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C.-P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, C. A. Smith, and R. G. Goodwin. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682.
16. -/- mice. Nat. Immunol 4: 255-260.
17. Bachmann, M. F., and R. M. Zinkernagel. 1997. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15: 235-270.
18. Bachmann, M. F., U. H. Rohrer, T. M. Kündig, K. Bürki, H. Hengartner, and R. M. Zinkernagel. 1993. The influence of antigen organization on B cell responsiveness. Science 262: 1448-1451.
19. Chackerian, B., D. R. Lowy, and J. T. Schiller. 2001. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108: 415-423.
20. Jegerlehner, A., A. Tissot, F. Lechner, P. Sebbel, I. Erdmann, T. Kündig, T. Bächi, T. Storni, G. Jennings, P. Pumpens, et al. 2002. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20: 3104-3112.
21. Chackerian, B., P. Lenz, D. R. Lowy, and J. T. Schiller. 2002. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol. 169: 6120-6126.
22. Cielens, I., V. Ose, I. Petrovskis, A. Strelnikova, R. Renhofa, T. Kozlovska, and P. Pumpens. 2000. Mutilation of RNA phage Qβ virus-like particles: from icosahedrons to rods. FEBS Lett. 482: 261-264.
23. Storni, T., F. Lechner, I. Erdmann, T. Bächi, A. Jegerlehner, T. Dumrese, T. M. Kündig, C. Ruedl, and M. F. Bachmann. 2002. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J. Immunol. 168: 2880-2886.
24. Lechner, F., A. Jegerlehner, A. C. Tissot, P. Maurer, P. Sebbel, W. A. Renner, G. T. Jennings, and M. F. Bachmann. 2002. Virus-like particles as a modular system for novel vaccines. Intervirology 45: 212-217.
25. Bachmann, M. F., B. R. Wong, R. Josien, R. M. Steinman, A. Oxenius, and Y. Choi. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 189: 1025-1031.
26. Dougall, W. C., M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De Smedt, E. Daro, J. Smith, M. E. Tometsko, C. R. Maliszewski, et al. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev. 13: 2412-2424.
27. Kong, Y.-Y., H. Yoshida, I. Sarosi, H.-L. Tan, E. Timms, C. Capparelli, S. Morony, A. J. Oliveira-dos-Santos, G. Van, A. Itie, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
28. Kim, D., R. E. Mebius, J. D. MacMicking, S. Jung, T. Cupedo, Y. Castellanos, J. Rho, B. R. Wong, R. Josien, N. Kim, et al. 2000. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J. Exp. Med. 192: 1467-1478.
29. Fata, J. E., Y.-Y. Kong, J. Li, T. Sasaki, J. Irie-Sasaki, R. A. Moorehead, R. Elliott, S. Scully, E. B. Voura, D. L. Lacey, et al. 2000. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103: 41-50.
30. Dalum, I., D. M. Butler, M. R. Jensen, P. Hindersson, L. Steinaa, A. M. Waterston, S. N. Grell, M. Feldmann, H. I. Eisner, and S. Mouritsen. 1999. Therapeutic antibodies elicited by immunization against TNF-α. Nat. Biotechnol. 17: 666-669.
31. Gardiner, S. M., T. R. Auton, M. R. Downham, H. L. Sharp, P. A. Kemp, J. E. March, H. Martin, P. J. Morgan, A. Rushton, T. Bennett, and J. F. Glover. 2000. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br. J. Pharmacol. 129: 1178-1182.
32. Hertz, M., S. Mahalingam, I. Dalum, S. Klysner, J. Mattes, A. Neisig, S. Mouritsen, P. S. Foster, and A. Gautam. 2001. Active vaccination against 1L-5 bypasses immunological tolerance and ameliorates experimental asthma. J. Immunol. 167: 3792-3799.
33. Hock, C., U. Konietzko, A. Papassotiropoulos, A. Wollmer, J. Streffer, R. C. von Rotz, G. Davey, E. Moritz, and R. M. Nitsch. 2002. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8: 1270-1275.
34. Orgogozo, J.-M., S. Gilman, J.-F. Dartigues, B. Laurent, M. Puel, L. C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61: 46-54.
35. Nicoll, J. A., D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9: 448-452.
36. Tew, J. G., R. P. Phipps, and T. E. Mandel. 1980. The maintenance and regulation of the humoral immune response: persisting antigen and the role of follicular antigen-binding dendritic cells as accessory cells. Immunol. Rev. 53: 175-201.
37. Bachmann, M. F., T. M. Kündig, H. Hengartner, and R. M. Zinkernagel. 1994. Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen. Eur. J. Immunol. 24: 2567-2570.
38. McHeyzer-Williams, M. G., and R. Ahmed. 1999. B cell memory and the long-lived plasma cell. Curr. Opin. Immunol. 11: 172-179.
39. Manz, R. A., S. Arce, G. Cassese, A. E. Hauser, F. Hiepe, and A. Radbruch. 2002. Humoral immunity and long-lived plasma cells. Curr. Opin. Immunol. 14: 517-521.
40. Bachmann, M. F., and M. R. Dyer. 2004. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat. Rev. Drug Discov. 3: 81-88.